- From
- United States
- Hospital for treatment
- Jiahui International Hospital, Shanghai
- Disease
- Advanced non-small cell lung cancer, combined with Parkinson's disease
- Treatment/medical stage
- Immunotherapy and multidisciplinary diagnosis and treatment
Existing treatment options are gradually decreasing
An American patient in his seventies, Daniel, suffers from advanced non-small cell lung cancer and Parkinson's disease. After receiving multiple lines of treatment in the United States, disease control was still unsatisfactory. An American doctor introduced the availability of ivonescimab in China, and the family further contacted Shanghai Jiahui to learn whether there were new treatment opportunities.
Evaluate not only the tumor, but also the overall condition
Daniel's children have a medical background and participated in the early communication. Because he faced both oncology and neurological diseases, the team needed to comprehensively consider previous medications, physical status, treatment tolerance, and hospital care, rather than deciding on the entire plan based on just one new drug.
New challenges arise during treatment
Reports record that patients develop immune-related adverse reactions during immunotherapy and require intensive care support. Jiahui organized collaboration among oncology, neurology and critical care medicine departments, and invited Professor Zhou Caicun to participate in the discussion; at the same time, Parkinson's disease medication was adjusted to deal with concurrent problems.
Continue treatment after stabilizing the condition
After the patient's condition stabilizes, he will be transferred back to the general ward and continue to receive treatment and observation. This case illustrates the search for new options when treatment options are limited, and the multidisciplinary team response to adverse effects. Public reports did not describe the results of this phase as a cancer cure.
Report source
Jiahui International Cancer Center · 2026-03-05 · View original report ↗
- 来自
- 美国
- 就诊医院
- 上海嘉会国际医院
- 疾病
- 晚期非小细胞肺癌，合并帕金森病
- 治疗／就医阶段
- 免疫治疗与多学科诊疗
已有治疗选择逐渐减少
七十多岁的美国患者 Daniel 患有晚期非小细胞肺癌，同时合并帕金森病。在美国接受多线治疗后，病情控制仍不理想。美国医生向其介绍依沃西单抗在中国的可及性，家人进一步联系上海嘉会，了解是否存在新的治疗机会。
不仅评估肿瘤，也评估整体状况
Daniel 的子女具有医学背景，参与了前期沟通。由于他同时面临肿瘤和神经系统疾病，团队需要综合考虑既往用药、身体状态、治疗耐受性和住院照护，而非仅以一种新药决定整个方案。
治疗过程中出现新的挑战
报道记载，患者在免疫治疗过程中发生免疫相关不良反应，需要重症监护支持。嘉会组织肿瘤科、神经内科和重症医学科协作，并请周彩存教授参与讨论；同时调整帕金森病用药，处理并发问题。
稳定病情后继续治疗
患者状况稳定后转回普通病房，继续接受治疗与观察。这个案例体现的是在治疗选择有限时寻找新方案，以及多学科团队对不良反应的应对。公开报道没有将该阶段的结果描述为癌症治愈。